| 1 | Explainable artificial intelligence in skin cancer recognition: A systematic review | 4.9 | 161 | Citations (PDF) |
| 2 | The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics | 5.3 | 50 | Citations (PDF) |
| 3 | Uncertainty Estimation in Medical Image Classification: Systematic Review | 9.4 | 70 | Citations (PDF) |
| 4 | Den Patienten wirklich verstehen lernen: Real-world-Evidenz aus der „patient journey“ | 0.5 | 6 | Citations (PDF) |
| 5 | Integrating proteomics into precision oncology | 4.3 | 25 | Citations (PDF) |
| 6 | Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients | 13.7 | 44 | Citations (PDF) |
| 7 | Renewed Absence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections in the Day Care Context in Berlin, January 2021 | 5.2 | 4 | Citations (PDF) |
| 8 | Robustness of convolutional neural networks in recognition of pigmented skin lesions | 4.9 | 54 | Citations (PDF) |
| 9 | Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study | 2.9 | 30 | Citations (PDF) |
| 10 | Deep learning approach to predict lymph node metastasis directly from primary tumour histology in prostate cancer | 3.2 | 66 | Citations (PDF) |
| 11 | The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision | 7.7 | 14 | Citations (PDF) |
| 12 | Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification | 4.9 | 98 | Citations (PDF) |
| 13 | MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer | 4.9 | 23 | Citations (PDF) |
| 14 | Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers | 25.1 | 268 | Citations (PDF) |
| 15 | Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study | 5.3 | 15 | Citations (PDF) |
| 16 | Deutschland krempelt die Ärmel hoch | 0.0 | 1 | Citations (PDF) |
| 17 | A time-resolved proteomic and prognostic map of COVID-19 | 5.8 | 184 | Citations (PDF) |
| 18 | Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study | 23.3 | 326 | Citations (PDF) |
| 19 | Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany | 3.8 | 77 | Citations (PDF) |
| 20 | A benchmark for neural network robustness in skin cancer classification | 4.9 | 61 | Citations (PDF) |
| 21 | Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts | 4.9 | 239 | Citations (PDF) |
| 22 | Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP) | 2.9 | 37 | Citations (PDF) |
| 23 | Deep learning can predict lymph node status directly from histology in colorectal cancer | 4.9 | 72 | Citations (PDF) |
| 24 | Überdiagnose von Melanomen – Ursachen, Konsequenzen und Lösungsansätze | 0.6 | 0 | Citations (PDF) |
| 25 | Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell CompartmentCell, 2020, 182, 1419-1440.e23 | 33.6 | 1,517 | Citations (PDF) |
| 26 | Overdiagnosis of melanoma – causes, consequences and solutions | 0.6 | 31 | Citations (PDF) |
| 27 | Externe wissenschaftliche Evaluation der ersten Teledermatologie-App ohne direkten Patientenkontakt in Deutschland („Online Hautarzt – AppDoc“) | 1.0 | 23 | Citations (PDF) |
| 28 | Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19) | 2.9 | 105 | Citations (PDF) |
| 29 | Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia | 7.7 | 8 | Citations (PDF) |
| 30 | COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis | 29.8 | 1,070 | Citations (PDF) |
| 31 | Sequencing of serially passaged measles virus affirms its genomic stability and reveals a nonrandom distribution of consensus mutations | 3.3 | 8 | Citations (PDF) |
| 32 | The German Corona Consensus Dataset (GECCO): a standardized dataset for COVID-19 research in university medicine and beyond | 3.1 | 69 | Citations (PDF) |
| 33 | Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data | 4.9 | 40 | Citations (PDF) |
| 34 | Deep neural networks are superior to dermatologists in melanoma image classification | 4.9 | 362 | Citations (PDF) |
| 35 | Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks | 4.9 | 193 | Citations (PDF) |
| 36 | Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images | 4.9 | 268 | Citations (PDF) |
| 37 | Superior skin cancer classification by the combination of human and artificial intelligence | 4.9 | 309 | Citations (PDF) |
| 38 | Enhanced classifier training to improve precision of a convolutional neural network to identify images of skin lesions | 2.3 | 33 | Citations (PDF) |
| 39 | Pathologist-level classification of histopathological melanoma images with deep neural networks | 4.9 | 204 | Citations (PDF) |
| 40 | A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task | 4.9 | 271 | Citations (PDF) |
| 41 | Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task | 4.9 | 514 | Citations (PDF) |
| 42 | Defective homologous recombination DNA repair as therapeutic target in advanced chordoma | 13.7 | 86 | Citations (PDF) |
| 43 | Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark | 4.9 | 144 | Citations (PDF) |
| 44 | Systematic comparative study of computational methods for T-cell receptor sequencing data analysis | 6.6 | 20 | Citations (PDF) |
| 45 | Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains | 6.5 | 32 | Citations (PDF) |
| 46 | Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia | 34.5 | 661 | Citations (PDF) |
| 47 | Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors | 6.8 | 103 | Citations (PDF) |
| 48 | Integrative genomic and transcriptomic analysis of leiomyosarcoma | 13.7 | 284 | Citations (PDF) |
| 49 | Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories | 33.0 | 299 | Citations (PDF) |
| 50 | A Face-Aging Smoking Prevention/Cessation Intervention for Nursery School Students in Germany: An Appearance-Focused Interventional Study | 2.9 | 7 | Citations (PDF) |
| 51 | NRG1
Fusions in
KRAS
Wild-Type Pancreatic Cancer | 25.1 | 236 | Citations (PDF) |
| 52 | Mapping Active Gene-Regulatory Regions in Human Repopulating Long-Term HSCs | 16.4 | 14 | Citations (PDF) |
| 53 | Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites | 4.9 | 37 | Citations (PDF) |
| 54 | Drug-perturbation-based stratification of blood cancer | 10.6 | 153 | Citations (PDF) |
| 55 | GENE-IS: Time-Efficient and Accurate Analysis of Viral Integration Events in Large-Scale Gene Therapy Data | 5.5 | 34 | Citations (PDF) |
| 56 | Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation | 5.4 | 75 | Citations (PDF) |
| 57 | Precision oncology based on omics data: The NCT Heidelberg experience | 4.3 | 164 | Citations (PDF) |
| 58 | Succession of transiently active tumor‐initiating cell clones in human pancreatic cancer xenografts | 7.1 | 44 | Citations (PDF) |
| 59 | Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer | 9.3 | 32 | Citations (PDF) |
| 60 | Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification | 4.1 | 39 | Citations (PDF) |
| 61 | Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation | 4.3 | 31 | Citations (PDF) |
| 62 | Lentiviral Vector Promoter is Decisive for Aberrant Transcript Formation | 3.2 | 10 | Citations (PDF) |
| 63 | Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma | 6.8 | 32 | Citations (PDF) |
| 64 | Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma | 9.9 | 33 | Citations (PDF) |
| 65 | Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society | 2.9 | 96 | Citations (PDF) |
| 66 | Between Minimal and Greater Than Minimal Risk: How Research Participants and Oncologists Assess Data-Sharing and the Risk of Re-identification in Genomic Research | 3.3 | 1 | Citations (PDF) |
| 67 | Synergizing genome editing and cancer immunotherapy | 1.2 | 0 | Citations (PDF) |
| 68 | Ultramicroscopy as a novel tool to unravel the tropism of AAV gene therapy vectors in the brain | 3.4 | 25 | Citations (PDF) |
| 69 | BRAF inhibition in hairy cell leukemia with low-dose vemurafenibBlood, 2016, 127, 2847-2855 | 5.0 | 121 | Citations (PDF) |
| 70 | Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification | 1.4 | 60 | Citations (PDF) |
| 71 | In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases | 16.4 | 225 | Citations (PDF) |
| 72 | Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases | 10.2 | 197 | Citations (PDF) |
| 73 | Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical StudyBlood, 2016, 128, 1175-1175 | 5.0 | 18 | Citations (PDF) |
| 74 | Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell DiseaseBlood, 2016, 128, 1176-1176 | 5.0 | 48 | Citations (PDF) |
| 75 | Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV | 4.1 | 23 | Citations (PDF) |
| 76 | Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation | 6.4 | 16 | Citations (PDF) |
| 77 | So rare we need to hunt for them: reframing the ethical debate on incidental findings | 9.6 | 19 | Citations (PDF) |
| 78 | High-throughput monitoring of integration site clonality in preclinical and clinical gene therapy studies | 4.1 | 12 | Citations (PDF) |
| 79 | The influence of low molecular weight heparin medication on plasma DNA in pregnant women | 2.3 | 57 | Citations (PDF) |
| 80 | Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory | 12.5 | 121 | Citations (PDF) |
| 81 | Fanconi Anemia Gene Editing by the CRISPR/Cas9 System | 3.2 | 109 | Citations (PDF) |
| 82 | Identification of NY‐BR‐1‐specific CD4+ T cell epitopes using HLA‐transgenic mice | 4.3 | 6 | Citations (PDF) |
| 83 | Cell Cycle Status of CD34+ Hemopoietic Stem Cells Determines Lentiviral Integration in Actively Transcribed and Development-related Genes | 10.2 | 13 | Citations (PDF) |
| 84 | TCR sequences and tissue distribution discriminate the subsets of naïve and activated/memory Treg cells in mice | 3.1 | 28 | Citations (PDF) |
| 85 | Lentivirus-induced ‘Smart’ dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma | 3.5 | 42 | Citations (PDF) |
| 86 | Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial | 2.9 | 73 | Citations (PDF) |
| 87 | High-resolution analysis of the human T-cell receptor repertoire | 13.7 | 134 | Citations (PDF) |
| 88 | Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling | 7.7 | 61 | Citations (PDF) |
| 89 | Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product)Blood, 2015, 126, 201-201 | 5.0 | 17 | Citations (PDF) |
| 90 | Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin VectorBlood, 2015, 126, 202-202 | 5.0 | 31 | Citations (PDF) |
| 91 | Cooperative Activity of BRAF F595L and Mutant HRAS in Histiocytic Sarcoma Provides New Insights into Oncogenic BRAF SignalingBlood, 2015, 126, 1631-1631 | 5.0 | 2 | Citations (PDF) |
| 92 | Comparison Between Several Integrase-defective Lentiviral Vectors Reveals Increased Integration of an HIV Vector Bearing a D167H Mutant | 5.5 | 12 | Citations (PDF) |
| 93 | Integration-deficient Lentiviral Vectors Expressing Codon-optimized R338L Human FIX Restore Normal Hemostasis in Hemophilia B Mice | 10.2 | 49 | Citations (PDF) |
| 94 | Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity | 12.5 | 533 | Citations (PDF) |
| 95 | Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition | 33.0 | 730 | Citations (PDF) |
| 96 | Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing | 37.9 | 438 | Citations (PDF) |
| 97 | Artificial riboswitches for gene expression and replication control of DNA and RNA viruses | 7.5 | 118 | Citations (PDF) |
| 98 | CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy | 10.2 | 275 | Citations (PDF) |
| 99 | Transgenic Expression of Human Glial Cell Line-Derived Neurotrophic Factor from Integration-Deficient Lentiviral Vectors is Neuroprotective in a Rodent Model of Parkinson's Disease | 3.2 | 22 | Citations (PDF) |
| 100 | Vector Integration and Tumorigenesis | 3.2 | 26 | Citations (PDF) |
| 101 | Uncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo | 10.2 | 183 | Citations (PDF) |
| 102 | Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma | 37.9 | 634 | Citations (PDF) |
| 103 | Linear Amplification Mediated PCR – Localization of Genetic Elements and Characterization of Unknown Flanking DNA | 0.3 | 13 | Citations (PDF) |
| 104 | Initial Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for β-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral βΑ-T87Q -Globin Vector (LentiGlobin BB305 Drug Product)Blood, 2014, 124, 549-549 | 5.0 | 10 | Citations (PDF) |
| 105 | Linear Amplification Mediated PCR – Localization of Genetic Elements and Characterization of Unknown Flanking DNA | 0.3 | 0 | Citations (PDF) |
| 106 | Next-generation sequencing of cancer consensus genes in lymphoma | 1.4 | 10 | Citations (PDF) |
| 107 | Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma | 25.2 | 795 | Citations (PDF) |
| 108 | Personalisierte Medizin und Informed Consent: Klinische und ethische Erwägungen im Rahmen der Entwicklung einer Best Practice Leitlinie für die biobankbasierte Ganzgenomforschung in der Onkologie | 0.8 | 3 | Citations (PDF) |
| 109 | Granulocyte-Macrophage Colony-Stimulating Factor-Armed Oncolytic Measles Virus Is an Effective Therapeutic Cancer Vaccine | 3.2 | 91 | Citations (PDF) |
| 110 | Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy | 36.2 | 1,118 | Citations (PDF) |
| 111 | Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome | 36.2 | 977 | Citations (PDF) |
| 112 | Chemovirotherapy of Malignant Melanoma with a Targeted and Armed Oncolytic Measles Virus | 2.3 | 36 | Citations (PDF) |
| 113 | Parallel assessment of globin lentiviral transfer in induced pluripotent stem cells and adult hematopoietic stem cells derived from the same transplanted β-thalassemia patient | 3.2 | 28 | Citations (PDF) |
| 114 | Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer | 33.0 | 314 | Citations (PDF) |
| 115 | Lentiviral vector–based insertional mutagenesis identifies genes associated with liver cancer | 24.6 | 102 | Citations (PDF) |
| 116 | TALEN-based Gene Correction for Epidermolysis Bullosa | 10.2 | 249 | Citations (PDF) |
| 117 | A largely random AAV integration profile after LPLD gene therapy | 33.0 | 187 | Citations (PDF) |
| 118 | From Bench to Bedside: Preclinical Evaluation of a Self-Inactivating Gammaretroviral Vector for the Gene Therapy of X-linked Chronic Granulomatous Disease | 3.6 | 22 | Citations (PDF) |
| 119 | The Fetal Mouse Is a Sensitive Genotoxicity Model That Exposes Lentiviral-associated Mutagenesis Resulting in Liver Oncogenesis | 10.2 | 22 | Citations (PDF) |
| 120 | Safety and Liver Transduction Efficacy of rAAV5-
cohPBGD
in Nonhuman Primates: A Potential Therapy for Acute Intermittent Porphyria | 3.2 | 60 | Citations (PDF) |
| 121 | Preclinical Safety and Efficacy of Human CD34+ Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome | 10.2 | 76 | Citations (PDF) |
| 122 | Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia | 16.9 | 68 | Citations (PDF) |
| 123 | Hematopoietic Stem Cell Gene Therapy For Wiskott- Aldrich SyndromeBlood, 2013, 122, 718-718 | 5.0 | 2 | Citations (PDF) |
| 124 | Long-Term Immunological Profile and T Cell Dynamics In Patients Treated With Allogeneic Transplantation and TK-Cells For Hematological MalignanciesBlood, 2013, 122, 165-165 | 5.0 | 0 | Citations (PDF) |
| 125 | Integration Frequency and Intermolecular Recombination of rAAV Vectors in Non-human Primate Skeletal Muscle and Liver | 10.2 | 106 | Citations (PDF) |
| 126 | BRAF Inhibition in Refractory Hairy-Cell Leukemia | 34.5 | 246 | Citations (PDF) |
| 127 | Stable Long-Term Blood Formation by Stem Cells in Murine Steady-State Hematopoiesis | 3.2 | 11 | Citations (PDF) |
| 128 | Integration of retroviral vectors | 5.2 | 25 | Citations (PDF) |
| 129 | Bioinformatic Clonality Analysis of Next-Generation Sequencing-Derived Viral Vector Integration Sites | 4.0 | 43 | Citations (PDF) |
| 130 | Extensive Methylation of Promoter Sequences Silences Lentiviral Transgene Expression During Stem Cell Differentiation In Vivo | 10.2 | 106 | Citations (PDF) |
| 131 | Dissecting the genomic complexity underlying medulloblastoma | 37.9 | 834 | Citations (PDF) |
| 132 | Translationale Onkologie – Effiziente Umsetzung onkologischer Grundlagenforschung | 0.2 | 3 | Citations (PDF) |
| 133 | Continued Response off Treatment After BRAF Inhibition in Refractory Hairy Cell LeukemiaBlood, 2012, 120, 4600-4600 | 5.0 | 0 | Citations (PDF) |
| 134 | Overexpression of EVI1 Causes Genomic Instability and Cell Cycle Arrest in Hematopoietic Cells.Blood, 2012, 120, 2398-2398 | 5.0 | 0 | Citations (PDF) |
| 135 | Distinct Types of Tumor-Initiating Cells Form Human Colon Cancer Tumors and Metastases | 16.4 | 290 | Citations (PDF) |
| 136 | An unbiased genome-wide analysis of zinc-finger nuclease specificity | 29.8 | 511 | Citations (PDF) |
| 137 | Analyzing the Number of Common Integration Sites of Viral Vectors – New Methods and Computer Programs | 2.3 | 24 | Citations (PDF) |
| 138 | Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selectionBlood, 2011, 117, 5332-5339 | 5.0 | 232 | Citations (PDF) |
| 139 | Correction of Murine SCID-X1 by Lentiviral Gene Therapy Using a Codon-optimized IL2RG Gene and Minimal Pretransplant Conditioning | 10.2 | 42 | Citations (PDF) |
| 140 | Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk | 10.1 | 131 | Citations (PDF) |
| 141 | Integration profile of retroviral vector in gene therapy treated patients is cell‐specific according to gene expression and chromatin conformation of target cell | 7.1 | 101 | Citations (PDF) |
| 142 | Stem Cell Gene Therapy for Fanconi Anemia: Report from the 1st International Fanconi Anemia Gene Therapy Working Group Meeting | 10.2 | 47 | Citations (PDF) |
| 143 | Stable Human FIX Expression After 0.9G Intrauterine Gene Transfer of Self-complementary Adeno-associated Viral Vector 5 and 8 in Macaques | 10.2 | 78 | Citations (PDF) |
| 144 | Lentiviral Vector Integration Profiles Differ in Rodent Postmitotic Tissues | 10.2 | 52 | Citations (PDF) |
| 145 | Insertion Sites in Engrafted Cells Cluster Within a Limited Repertoire of Genomic Areas After Gammaretroviral Vector Gene Therapy | 10.2 | 48 | Citations (PDF) |
| 146 | MicroRNA-sensitive Oncolytic Measles Viruses for Cancer-specific Vector Tropism | 10.2 | 97 | Citations (PDF) |
| 147 | Long-term Regulation of Genetically Modified Primary Hematopoietic Cells in Dogs | 10.2 | 15 | Citations (PDF) |
| 148 | Clonal Inventory Screens Uncover Monoclonality Following Serial Transplantation of
MGMT
P140K
-Transduced Stem Cells and Dose-Intense Chemotherapy | 3.2 | 17 | Citations (PDF) |
| 149 | Retroviral Gene Therapy for X-linked Chronic Granulomatous Disease: Results From Phase I/II Trial | 10.2 | 99 | Citations (PDF) |
| 150 | Retroviral Vectors: Post Entry Events and Genomic Alterations | 3.2 | 46 | Citations (PDF) |
| 151 | Efficacy of Gene Therapy for Wiskott-Aldrich-SyndromeBlood, 2011, 118, 165-165 | 5.0 | 2 | Citations (PDF) |
| 152 | Deregulated EVI1 Expression Leads to Genomic Instability and G1 Cell Cycle ArrestBlood, 2011, 118, 2431-2431 | 5.0 | 0 | Citations (PDF) |
| 153 | Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease | 33.0 | 775 | Citations (PDF) |
| 154 | The Inherent Differentiation Program of Short-Term Hematopoietic Repopulating Cells Changes During Human Ontogeny | 2.0 | 3 | Citations (PDF) |
| 155 | Lentivirus-mediated Reprogramming of Somatic Cells in the Absence of Transgenic Transcription Factors | 10.2 | 38 | Citations (PDF) |
| 156 | Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome | 34.5 | 534 | Citations (PDF) |
| 157 | Retroviral Vectors for Gene Therapy | 2.0 | 46 | Citations (PDF) |
| 158 | 10-Year stability of clinical-grade serum-free γ-retroviral vector-containing medium | 3.5 | 4 | Citations (PDF) |
| 159 | Thérapie génique de l’adrénoleucodystrophie liée à l’X par transfert du gène dans les cellules souches hématopoïétiques à l’aide d’un vecteur lentiviral | 0.1 | 10 | Citations (PDF) |
| 160 | High-Definition Mapping of Retroviral Integration Sites Defines the Fate of Allogeneic T Cells After Donor Lymphocyte Infusion | 2.3 | 42 | Citations (PDF) |
| 161 | Uncovering Haematopoietic System Dynamics and Single Multipotent Progenitors Activity In Vivo In Humans by Retroviral Tagging.Blood, 2010, 116, 2611-2611 | 5.0 | 0 | Citations (PDF) |
| 162 | Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells | 33.0 | 268 | Citations (PDF) |
| 163 | Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy | 36.2 | 1,472 | Citations (PDF) |
| 164 | The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy | 10.6 | 531 | Citations (PDF) |
| 165 | Inhibition of HIF1A Signaling by a Novel Class of Sulfonanilides for Targeted Treatment of Multiple Myeloma.Blood, 2009, 114, 2856-2856 | 5.0 | 2 | Citations (PDF) |
| 166 | In Vivo Lentiviral Marking Demonstrates Long-Term Myeloid and Lymphoid Lineage Contribution of Individual Hematopoietic Stem Cell Clones to Murine Steady-State Hematopoiesis.Blood, 2009, 114, 813-813 | 5.0 | 0 | Citations (PDF) |
| 167 | Adeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate Muscle | 3.6 | 279 | Citations (PDF) |
| 168 | Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients | 10.6 | 1,211 | Citations (PDF) |
| 169 | Hematopoietic Stem Cell Gene Therapy Trial with Lentiviral Vector in X-Linked AdrenoleukodystrophyBlood, 2008, 112, 821-821 | 5.0 | 3 | Citations (PDF) |
| 170 | Comprehensive and Unbiased Integration Site Analysis in Clinical Gene Therapy.Blood, 2008, 112, 2351-2351 | 5.0 | 0 | Citations (PDF) |
| 171 | Hematopoietic Activity of Human Short Term Repopulating Cells in Mobilized Peripheral Blood Cell Transplants Is Restricted to the First 5Months after Transplantation.Blood, 2008, 112, 1386-1386 | 5.0 | 0 | Citations (PDF) |
| 172 | Non-Random Lentiviral Vector Insertions in Bone Marrow Progenitors from Fanconi Anemia PatientsBlood, 2008, 112, 2358-2358 | 5.0 | 0 | Citations (PDF) |
| 173 | Stem Cell Collection and Gene Transfer in Fanconi Anemia | 10.2 | 172 | Citations (PDF) |
| 174 | Importance of Murine Study Design for Testing Toxicity of Retroviral Vectors in Support of Phase I Trials | 10.2 | 26 | Citations (PDF) |
| 175 | Hot spots of retroviral integration in human CD34+ hematopoietic cellsBlood, 2007, 110, 1770-1778 | 5.0 | 264 | Citations (PDF) |
| 176 | Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy | 10.6 | 236 | Citations (PDF) |
| 177 | Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo | 10.6 | 192 | Citations (PDF) |
| 178 | Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome.Blood, 2007, 110, 502-502 | 5.0 | 7 | Citations (PDF) |
| 179 | Real-Time Definition of Non-Randomness in the Distribution of Genomic Events | 2.3 | 29 | Citations (PDF) |
| 180 | The Clonal Inventory of Gene Corrected Hematopoiesis in Three Successful Clinical Gene Therapy TrialsBlood, 2007, 110, 3733-3733 | 5.0 | 0 | Citations (PDF) |
| 181 | Phase I/II Gene Therapy Study for Chronic Granulomatous Disease: Results, Lessons and Perspectives.Blood, 2007, 110, 503-503 | 5.0 | 0 | Citations (PDF) |
| 182 | A Hybrid Vector for Ligand-Directed Tumor Targeting and Molecular Imaging | 33.6 | 264 | Citations (PDF) |
| 183 | Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicityBlood, 2006, 108, 2545-2553 | 5.0 | 320 | Citations (PDF) |
| 184 | Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaqueBlood, 2006, 107, 3865-3867 | 5.0 | 131 | Citations (PDF) |
| 185 | Therapeutic gene causing lymphoma | 37.9 | 274 | Citations (PDF) |
| 186 | Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration | 29.8 | 688 | Citations (PDF) |
| 187 | Effective gene therapy with nonintegrating lentiviral vectors | 33.0 | 440 | Citations (PDF) |
| 188 | Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 | 33.0 | 1,183 | Citations (PDF) |
| 189 | Fragile sites are preferential targets for integrations of MLV vectors in gene therapy | 3.5 | 48 | Citations (PDF) |
| 190 | Lentiviral vectors pseudotyped with murine ecotropic envelope: Increased biosafety and convenience in preclinical research | 0.4 | 105 | Citations (PDF) |
| 191 | Bone marrow-derived cells contribute to infarct remodelling | 5.5 | 180 | Citations (PDF) |
| 192 | 97. Translational Studies toward Optimizing In Vivo Bone Marrow Stem Cell Gene Transfer Using Lentiviral Vector | 10.2 | 0 | Citations (PDF) |
| 193 | In Vivo Gene Transfer into Adult Stem Cells in Unconditioned Mice by in Situ Delivery of a Lentiviral Vector | 10.2 | 48 | Citations (PDF) |
| 194 | Low-dose total body irradiation causes clonal fluctuation of primate hematopoietic stem and progenitor cellsBlood, 2005, 105, 1010-1015 | 5.0 | 23 | Citations (PDF) |
| 195 | Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trialBlood, 2005, 105, 2699-2706 | 5.0 | 75 | Citations (PDF) |
| 196 | Efficient marking of human cells with rapid but transient repopulating activity in autografted recipientsBlood, 2005, 106, 893-898 | 5.0 | 33 | Citations (PDF) |
| 197 | Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesisBlood, 2005, 105, 4235-4246 | 5.0 | 181 | Citations (PDF) |
| 198 | Failure of SCID-X1 gene therapy in older patientsBlood, 2005, 105, 4255-4257 | 5.0 | 132 | Citations (PDF) |
| 199 | Evidence of similar effects of short-term culture on the initial repopulating activity of mobilized peripheral blood transplants assessed in NOD/SCID-β2microglobulinnull mice and in autografted patients | 0.4 | 7 | Citations (PDF) |
| 200 | Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34+ cells | 10.2 | 77 | Citations (PDF) |
| 201 | Oncogenesis Following Delivery of a Nonprimate Lentiviral Gene Therapy Vector to Fetal and Neonatal Mice | 10.2 | 243 | Citations (PDF) |
| 202 | Long-Term Clinical and Molecular Follow-up of Large Animals Receiving Retrovirally Transduced Stem and Progenitor Cells: No Progression to Clonal Hematopoiesis or Leukemia | 10.2 | 94 | Citations (PDF) |
| 203 | LMO2and Gene Therapy for Severe Combined Immunodeficiency | 34.5 | 57 | Citations (PDF) |
| 204 | Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor Cells | 5.0 | 247 | Citations (PDF) |
| 205 | Chance or necessity? Insertional Mutagenesis in Gene Therapy and Its Consequences | 10.2 | 220 | Citations (PDF) |
| 206 | Stem cell clonality and genotoxicity in hematopoietic cells: Gene activation side effects should be avoidable | 3.1 | 32 | Citations (PDF) |
| 207 | Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector | 62.1 | 657 | Citations (PDF) |
| 208 | Effect of chronic cytokine therapy on clonal dynamics in nonhuman primatesBlood, 2004, 103, 4070-4077 | 5.0 | 14 | Citations (PDF) |
| 209 | Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates | 33.0 | 135 | Citations (PDF) |
| 210 | Efficient Characterization of Retro‐, Lenti‐, and Foamyvector‐Transduced Cell Populations by High‐Accuracy Insertion Site Sequencing | 4.0 | 22 | Citations (PDF) |
| 211 | A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency | 34.5 | 1,820 | Citations (PDF) |
| 212 | Comparison of Three Retroviral Vector Systems for Transduction of Nonobese Diabetic/Severe Combined Immunodeficiency Mice Repopulating Human CD34+Cord Blood Cells | 3.2 | 120 | Citations (PDF) |
| 213 | Retrovirally transduced muscle-derived cells contribute to hematopoiesis at very low levels in the nonhuman primate model | 10.2 | 3 | Citations (PDF) |
| 214 | Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesisBlood, 2003, 101, 1284-1289 | 5.0 | 198 | Citations (PDF) |
| 215 | Side effects of retroviral gene transfer into hematopoietic stem cellsBlood, 2003, 101, 2099-2113 | 5.0 | 410 | Citations (PDF) |
| 216 | Chance or necessity? Insertional Mutagenesis in Gene Therapy and Its Consequences | 10.2 | 0 | Citations (PDF) |
| 217 | Methylguanine methyltransferase–mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model | 10.6 | 45 | Citations (PDF) |
| 218 | Methylguanine methyltransferase–mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model | 10.6 | 112 | Citations (PDF) |
| 219 | Polyclonal long-term repopulating stem cell clones in a primate modelBlood, 2002, 100, 2737-2743 | 5.0 | 223 | Citations (PDF) |
| 220 | Pharmacologically regulated in vivo selection in a large animalBlood, 2002, 100, 2026-2031 | 5.0 | 73 | Citations (PDF) |
| 221 | Molecular Evidence of Lentiviral Vector-Mediated Gene Transfer into Human Self-Renewing, Multi-potent, Long-Term NOD/SCID Repopulating Hematopoietic Cells | 10.2 | 24 | Citations (PDF) |
| 222 | Molecular Evidence of Lentiviral Vector-Mediated Gene Transfer into Human Self-Renewing, Multi-potent, Long-Term NOD/SCID Repopulating Hematopoietic Cells | 10.2 | 94 | Citations (PDF) |
| 223 | Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model | 6.5 | 30 | Citations (PDF) |
| 224 | Detection and Direct Genomic Sequencing of Multiple Rare Unknown Flanking DNA in Highly Complex Samples | 3.2 | 166 | Citations (PDF) |
| 225 | A Model for the Detection of Clonality in Marked Hematopoietic Stem Cells | 4.0 | 25 | Citations (PDF) |
| 226 | Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-β2 microglobulin–null mice | 10.6 | 173 | Citations (PDF) |
| 227 | Production of stem-cell transplants according to good manufacturing practice | 1.5 | 21 | Citations (PDF) |
| 228 | Efficient Serum-Free Retroviral Gene Transfer into Primitive Human Hematopoietic Progenitor Cells by a Defined, High-Titer, Nonconcentrated Vector-Containing Medium | 3.2 | 25 | Citations (PDF) |
| 229 | New developments in hematopoietic stem cell expansion | 2.8 | 19 | Citations (PDF) |
| 230 | Efficient Gene Transfer in Primitive CD34
+
/CD38
lo
Human Bone Marrow Cells Reselected after Long-Term Exposure to GALV-Pseudotyped Retroviral Vector | 3.2 | 23 | Citations (PDF) |
| 231 | Long-Term Persistence of Canine Hematopoietic Cells Genetically Marked by Retrovirus Vectors | 3.2 | 40 | Citations (PDF) |
| 232 | Gene therapy and bone marrow transplantation | 2.1 | 13 | Citations (PDF) |
| 233 | Growth of hodgkin cell lines in severely combined immunodeficient mice | 4.3 | 35 | Citations (PDF) |
| 234 | Evaluating a Chatbot as a Companion for Patients With Breast Cancer: Collaborative Pilot Study | 2.1 | 10 | Citations (PDF) |
